high-risk lymphoma: the zuma-1 and scholar-1 trials
Published 4 years ago • 285 plays • Length 8:01Download video MP4
Download video MP3
Similar videos
-
2:24
dr. neelapu on axi-cel in the zuma-1 trial for refractory aggressive non-hodgkin lymphoma
-
2:02
dr. neelapu on updated zuma-1 findings in non-hodgkin lymphoma
-
2:02
discussing the results from the zuma-1 trial for patients with advanced lymphoma
-
2:48
zuma-1: safety and efficacy of axicabtagene in refractory non-hodgkin lymphoma patients
-
2:24
zuma-1: a pivotal trial of axicabtagene ciloleucel (axi-cel; kte-c19) in patients with nhl
-
3:16
zuma-12: a phase 2 study of axi-cel as first-line therapy in patients with high-risk large b-cel...
-
5:50
large b-cell lymphoma: zuma-1 trial
-
1:44
comparison of zuma-1 and scholar-1 outcomes
-
5:11
traditional therapies for high-risk lymphoma and efficacy
-
2:17
zuma-12: axicabtagene ciloleucel as a first-line therapy in patients with high-risk lbcl
-
3:32
zuma-1: updated data and future prospects
-
2:38
zuma-1 & scholar-1: comparison of outcomes in refractory dlbcl
-
2:59
axi-cel in older patients: data from zuma-1 and clinical use
-
6:03
clinical data for axi-cel in lymphoma
-
2:00
long-term follow-up results of the zuma-1 trial of anti-cd19 car t-cells for non-hodgkin lymphoma
-
3:55
zuma-12: axicabtagene ciloleucel for high-risk large b cell lymphoma
-
2:06
zuma-12: axi-cel as first-line therapy in high-risk large b-cell lymphoma
-
2:00
zuma-1 trial: fda approval and follow-up of car t-cell product axicabtagene ciloleucel
-
2:09
zuma series update: zuma-1 and zuma-2